By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Investment bank Mizuho Securities USA has upgraded its ratings on PerkinElmer and Becton Dickinson to Outperform from Neutral.

Analyst Peter Lawson raised PerkinElmer's rating and placed a $25 price target on its stock. He said the firm has less exposure to high-risk end markets, such as academic, pharma, and government, compared to its peers. He also said that business mix is more insulated from a cyclical downturn.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: factors influencing retrotransposon integration sites, and more.

A bioethicist argues for the responsible use of germline gene editing.

Some breweries are using DNA-based testing to determine whether unwanted bacteria are affecting their beers, The Verge reports.

Standardized N-of-1 trials will be needed to test out personalized medicines, writes Nicholas Schork from the J. Craig Venter Institute at Nature.